富祥药业(300497.SZ)通过美国FDA现场检查

Core Viewpoint - Fuxiang Pharmaceutical successfully passed the FDA's cGMP inspection, indicating its compliance with international quality standards and enhancing its capability to supply commercial intermediates and APIs to the US and global markets [1] Group 1: FDA Inspection Results - The company underwent an FDA cGMP inspection from August 11 to August 14, 2025, covering various GMP systems including quality, material management, production, equipment, packaging, labeling, and laboratory control [1] - The inspection resulted in a VAI (Voluntary Action Indicated) outcome, marking the third successful cGMP inspection by the FDA for the company [1] Group 2: Implications for the Company - The successful inspection reflects the company's commitment to high international quality standards and validates the effective operation of its management systems [1] - This achievement is expected to boost the company's competitiveness and support its goals for international market expansion [1]